nodes	percent_of_prediction	percent_of_DWPC	metapath
Alfuzosin—Oedema due to cardiac disease—Capecitabine—colon cancer	0.19	0.196	CcSEcCtD
Alfuzosin—Coronary artery disease—Vincristine—colon cancer	0.0255	0.0264	CcSEcCtD
Alfuzosin—Miosis—Irinotecan—colon cancer	0.0235	0.0243	CcSEcCtD
Alfuzosin—Terazosin—ABCB1—colon cancer	0.013	0.412	CrCbGaD
Alfuzosin—Doxazosin—ABCB1—colon cancer	0.0097	0.306	CrCbGaD
Alfuzosin—Neuropathy—Vincristine—colon cancer	0.00948	0.00979	CcSEcCtD
Alfuzosin—Neuralgia—Capecitabine—colon cancer	0.00947	0.00978	CcSEcCtD
Alfuzosin—Torsade de pointes—Capecitabine—colon cancer	0.00939	0.00969	CcSEcCtD
Alfuzosin—Laryngitis—Capecitabine—colon cancer	0.00913	0.00943	CcSEcCtD
Alfuzosin—Prazosin—ABCB1—colon cancer	0.00894	0.282	CrCbGaD
Alfuzosin—Injury—Irinotecan—colon cancer	0.00777	0.00802	CcSEcCtD
Alfuzosin—Osteoarthritis—Irinotecan—colon cancer	0.00714	0.00737	CcSEcCtD
Alfuzosin—Osteoarthritis—Fluorouracil—colon cancer	0.00684	0.00706	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Irinotecan—colon cancer	0.00652	0.00673	CcSEcCtD
Alfuzosin—Influenza like illness—Capecitabine—colon cancer	0.00639	0.0066	CcSEcCtD
Alfuzosin—Neuropathy—Capecitabine—colon cancer	0.00618	0.00638	CcSEcCtD
Alfuzosin—Angina pectoris—Irinotecan—colon cancer	0.00601	0.00621	CcSEcCtD
Alfuzosin—Erectile dysfunction—Vincristine—colon cancer	0.00584	0.00603	CcSEcCtD
Alfuzosin—Angina pectoris—Fluorouracil—colon cancer	0.00576	0.00594	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Irinotecan—colon cancer	0.00573	0.00592	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Vincristine—colon cancer	0.00554	0.00572	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Fluorouracil—colon cancer	0.00549	0.00567	CcSEcCtD
Alfuzosin—Sweating—Vincristine—colon cancer	0.00542	0.00559	CcSEcCtD
Alfuzosin—Jaundice—Irinotecan—colon cancer	0.00536	0.00554	CcSEcCtD
Alfuzosin—Sweating—Irinotecan—colon cancer	0.00527	0.00545	CcSEcCtD
Alfuzosin—Infestation NOS—Fluorouracil—colon cancer	0.00527	0.00544	CcSEcCtD
Alfuzosin—Infestation—Fluorouracil—colon cancer	0.00527	0.00544	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Fluorouracil—colon cancer	0.00516	0.00533	CcSEcCtD
Alfuzosin—Atrial fibrillation—Capecitabine—colon cancer	0.00504	0.00521	CcSEcCtD
Alfuzosin—Urinary tract disorder—Vincristine—colon cancer	0.00501	0.00517	CcSEcCtD
Alfuzosin—Connective tissue disorder—Vincristine—colon cancer	0.00498	0.00515	CcSEcCtD
Alfuzosin—Urethral disorder—Vincristine—colon cancer	0.00497	0.00513	CcSEcCtD
Alfuzosin—Rhinitis—Irinotecan—colon cancer	0.00495	0.00511	CcSEcCtD
Alfuzosin—Sinusitis—Fluorouracil—colon cancer	0.00494	0.00511	CcSEcCtD
Alfuzosin—Arthritis—Capecitabine—colon cancer	0.00492	0.00508	CcSEcCtD
Alfuzosin—Connective tissue disorder—Irinotecan—colon cancer	0.00485	0.00501	CcSEcCtD
Alfuzosin—Osteoarthritis—Capecitabine—colon cancer	0.00478	0.00493	CcSEcCtD
Alfuzosin—Rhinitis—Fluorouracil—colon cancer	0.00474	0.0049	CcSEcCtD
Alfuzosin—Cardiac disorder—Vincristine—colon cancer	0.00471	0.00486	CcSEcCtD
Alfuzosin—Pharyngitis—Fluorouracil—colon cancer	0.00469	0.00485	CcSEcCtD
Alfuzosin—Angiopathy—Vincristine—colon cancer	0.0046	0.00475	CcSEcCtD
Alfuzosin—Flushing—Irinotecan—colon cancer	0.00458	0.00473	CcSEcCtD
Alfuzosin—Cardiac disorder—Irinotecan—colon cancer	0.00458	0.00473	CcSEcCtD
Alfuzosin—Mediastinal disorder—Vincristine—colon cancer	0.00457	0.00472	CcSEcCtD
Alfuzosin—Angiopathy—Irinotecan—colon cancer	0.00448	0.00463	CcSEcCtD
Alfuzosin—Mediastinal disorder—Irinotecan—colon cancer	0.00445	0.0046	CcSEcCtD
Alfuzosin—Mental disorder—Vincristine—colon cancer	0.00444	0.00459	CcSEcCtD
Alfuzosin—Orthostatic hypotension—Capecitabine—colon cancer	0.00436	0.00451	CcSEcCtD
Alfuzosin—Abdominal pain upper—Capecitabine—colon cancer	0.00436	0.00451	CcSEcCtD
Alfuzosin—Breast disorder—Capecitabine—colon cancer	0.00432	0.00446	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Capecitabine—colon cancer	0.0043	0.00444	CcSEcCtD
Alfuzosin—Back pain—Vincristine—colon cancer	0.00427	0.00441	CcSEcCtD
Alfuzosin—Back pain—Irinotecan—colon cancer	0.00416	0.00429	CcSEcCtD
Alfuzosin—Angina pectoris—Capecitabine—colon cancer	0.00402	0.00415	CcSEcCtD
Alfuzosin—Ill-defined disorder—Irinotecan—colon cancer	0.00399	0.00412	CcSEcCtD
Alfuzosin—Bronchitis—Capecitabine—colon cancer	0.00397	0.0041	CcSEcCtD
Alfuzosin—Vertigo—Vincristine—colon cancer	0.00397	0.0041	CcSEcCtD
Alfuzosin—Malaise—Irinotecan—colon cancer	0.00388	0.004	CcSEcCtD
Alfuzosin—Vertigo—Irinotecan—colon cancer	0.00386	0.00399	CcSEcCtD
Alfuzosin—Syncope—Irinotecan—colon cancer	0.00386	0.00398	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Capecitabine—colon cancer	0.00384	0.00396	CcSEcCtD
Alfuzosin—Loss of consciousness—Irinotecan—colon cancer	0.00378	0.0039	CcSEcCtD
Alfuzosin—Infestation NOS—Capecitabine—colon cancer	0.00368	0.0038	CcSEcCtD
Alfuzosin—Infestation—Capecitabine—colon cancer	0.00368	0.0038	CcSEcCtD
Alfuzosin—Discomfort—Irinotecan—colon cancer	0.00362	0.00373	CcSEcCtD
Alfuzosin—Neuropathy peripheral—Capecitabine—colon cancer	0.00361	0.00373	CcSEcCtD
Alfuzosin—Oedema—Vincristine—colon cancer	0.0036	0.00372	CcSEcCtD
Alfuzosin—Jaundice—Capecitabine—colon cancer	0.00359	0.00371	CcSEcCtD
Alfuzosin—Infection—Vincristine—colon cancer	0.00358	0.0037	CcSEcCtD
Alfuzosin—Osteoarthritis—Methotrexate—colon cancer	0.00356	0.00367	CcSEcCtD
Alfuzosin—Nervous system disorder—Vincristine—colon cancer	0.00353	0.00365	CcSEcCtD
Alfuzosin—Thrombocytopenia—Vincristine—colon cancer	0.00353	0.00364	CcSEcCtD
Alfuzosin—Oedema—Irinotecan—colon cancer	0.00351	0.00362	CcSEcCtD
Alfuzosin—Chest pain—Fluorouracil—colon cancer	0.00351	0.00362	CcSEcCtD
Alfuzosin—Infection—Irinotecan—colon cancer	0.00349	0.0036	CcSEcCtD
Alfuzosin—Hyperhidrosis—Vincristine—colon cancer	0.00348	0.0036	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Capecitabine—colon cancer	0.00348	0.0036	CcSEcCtD
Alfuzosin—Discomfort—Fluorouracil—colon cancer	0.00346	0.00358	CcSEcCtD
Alfuzosin—Shock—Irinotecan—colon cancer	0.00345	0.00356	CcSEcCtD
Alfuzosin—Nervous system disorder—Irinotecan—colon cancer	0.00344	0.00355	CcSEcCtD
Alfuzosin—Thrombocytopenia—Irinotecan—colon cancer	0.00344	0.00355	CcSEcCtD
Alfuzosin—Hyperhidrosis—Irinotecan—colon cancer	0.00339	0.0035	CcSEcCtD
Alfuzosin—Hypotension—Vincristine—colon cancer	0.00337	0.00348	CcSEcCtD
Alfuzosin—Oedema—Fluorouracil—colon cancer	0.00336	0.00347	CcSEcCtD
Alfuzosin—Infection—Fluorouracil—colon cancer	0.00334	0.00345	CcSEcCtD
Alfuzosin—Rhinitis—Capecitabine—colon cancer	0.00331	0.00342	CcSEcCtD
Alfuzosin—Nervous system disorder—Fluorouracil—colon cancer	0.0033	0.0034	CcSEcCtD
Alfuzosin—Thrombocytopenia—Fluorouracil—colon cancer	0.00329	0.0034	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Vincristine—colon cancer	0.00328	0.00339	CcSEcCtD
Alfuzosin—Pharyngitis—Capecitabine—colon cancer	0.00328	0.00339	CcSEcCtD
Alfuzosin—Tachycardia—Fluorouracil—colon cancer	0.00328	0.00339	CcSEcCtD
Alfuzosin—Hypotension—Irinotecan—colon cancer	0.00328	0.00339	CcSEcCtD
Alfuzosin—Urinary tract disorder—Capecitabine—colon cancer	0.00326	0.00337	CcSEcCtD
Alfuzosin—Connective tissue disorder—Capecitabine—colon cancer	0.00325	0.00335	CcSEcCtD
Alfuzosin—Urethral disorder—Capecitabine—colon cancer	0.00324	0.00335	CcSEcCtD
Alfuzosin—Breast disorder—Methotrexate—colon cancer	0.00321	0.00332	CcSEcCtD
Alfuzosin—Toxic epidermal necrolysis—Methotrexate—colon cancer	0.0032	0.00331	CcSEcCtD
Alfuzosin—Hypotension—Fluorouracil—colon cancer	0.00314	0.00324	CcSEcCtD
Alfuzosin—Somnolence—Irinotecan—colon cancer	0.00312	0.00322	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Vincristine—colon cancer	0.00311	0.00321	CcSEcCtD
Alfuzosin—Fatigue—Vincristine—colon cancer	0.00311	0.00321	CcSEcCtD
Alfuzosin—Eye disorder—Capecitabine—colon cancer	0.00309	0.00319	CcSEcCtD
Alfuzosin—Dyspepsia—Irinotecan—colon cancer	0.00309	0.00319	CcSEcCtD
Alfuzosin—Constipation—Vincristine—colon cancer	0.00308	0.00318	CcSEcCtD
Alfuzosin—Pain—Vincristine—colon cancer	0.00308	0.00318	CcSEcCtD
Alfuzosin—Flushing—Capecitabine—colon cancer	0.00307	0.00317	CcSEcCtD
Alfuzosin—Cardiac disorder—Capecitabine—colon cancer	0.00307	0.00317	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Fluorouracil—colon cancer	0.00306	0.00316	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Irinotecan—colon cancer	0.00303	0.00313	CcSEcCtD
Alfuzosin—Fatigue—Irinotecan—colon cancer	0.00303	0.00312	CcSEcCtD
Alfuzosin—Pain—Irinotecan—colon cancer	0.003	0.0031	CcSEcCtD
Alfuzosin—Constipation—Irinotecan—colon cancer	0.003	0.0031	CcSEcCtD
Alfuzosin—Angiopathy—Capecitabine—colon cancer	0.003	0.0031	CcSEcCtD
Alfuzosin—Somnolence—Fluorouracil—colon cancer	0.00299	0.00309	CcSEcCtD
Alfuzosin—Mediastinal disorder—Capecitabine—colon cancer	0.00298	0.00308	CcSEcCtD
Alfuzosin—Dyspepsia—Fluorouracil—colon cancer	0.00296	0.00305	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Vincristine—colon cancer	0.00295	0.00304	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Fluorouracil—colon cancer	0.0029	0.003	CcSEcCtD
Alfuzosin—Mental disorder—Capecitabine—colon cancer	0.0029	0.00299	CcSEcCtD
Alfuzosin—Feeling abnormal—Irinotecan—colon cancer	0.00289	0.00299	CcSEcCtD
Alfuzosin—Pain—Fluorouracil—colon cancer	0.00287	0.00297	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Irinotecan—colon cancer	0.00287	0.00296	CcSEcCtD
Alfuzosin—Upper respiratory tract infection—Methotrexate—colon cancer	0.00286	0.00295	CcSEcCtD
Alfuzosin—Abdominal pain—Vincristine—colon cancer	0.00285	0.00294	CcSEcCtD
Alfuzosin—Erectile dysfunction—Methotrexate—colon cancer	0.00283	0.00292	CcSEcCtD
Alfuzosin—Back pain—Capecitabine—colon cancer	0.00278	0.00287	CcSEcCtD
Alfuzosin—Abdominal pain—Irinotecan—colon cancer	0.00277	0.00286	CcSEcCtD
Alfuzosin—Feeling abnormal—Fluorouracil—colon cancer	0.00277	0.00286	CcSEcCtD
Alfuzosin—Infestation NOS—Methotrexate—colon cancer	0.00274	0.00283	CcSEcCtD
Alfuzosin—Infestation—Methotrexate—colon cancer	0.00274	0.00283	CcSEcCtD
Alfuzosin—Drowsiness—Methotrexate—colon cancer	0.00274	0.00283	CcSEcCtD
Alfuzosin—Ill-defined disorder—Capecitabine—colon cancer	0.00267	0.00276	CcSEcCtD
Alfuzosin—Urticaria—Fluorouracil—colon cancer	0.00267	0.00276	CcSEcCtD
Alfuzosin—Sweating—Methotrexate—colon cancer	0.00263	0.00271	CcSEcCtD
Alfuzosin—Malaise—Capecitabine—colon cancer	0.00259	0.00268	CcSEcCtD
Alfuzosin—Hepatobiliary disease—Methotrexate—colon cancer	0.00259	0.00268	CcSEcCtD
Alfuzosin—Vertigo—Capecitabine—colon cancer	0.00259	0.00267	CcSEcCtD
Alfuzosin—Asthenia—Vincristine—colon cancer	0.00258	0.00267	CcSEcCtD
Alfuzosin—Syncope—Capecitabine—colon cancer	0.00258	0.00266	CcSEcCtD
Alfuzosin—Palpitations—Capecitabine—colon cancer	0.00254	0.00263	CcSEcCtD
Alfuzosin—Loss of consciousness—Capecitabine—colon cancer	0.00253	0.00261	CcSEcCtD
Alfuzosin—Asthenia—Irinotecan—colon cancer	0.00252	0.0026	CcSEcCtD
Alfuzosin—Diarrhoea—Vincristine—colon cancer	0.00247	0.00255	CcSEcCtD
Alfuzosin—Arthralgia—Capecitabine—colon cancer	0.00245	0.00253	CcSEcCtD
Alfuzosin—Chest pain—Capecitabine—colon cancer	0.00245	0.00253	CcSEcCtD
Alfuzosin—Pharyngitis—Methotrexate—colon cancer	0.00244	0.00252	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—colon cancer	0.00243	0.00251	CcSEcCtD
Alfuzosin—Urinary tract disorder—Methotrexate—colon cancer	0.00243	0.00251	CcSEcCtD
Alfuzosin—Discomfort—Capecitabine—colon cancer	0.00242	0.0025	CcSEcCtD
Alfuzosin—Urethral disorder—Methotrexate—colon cancer	0.00241	0.00249	CcSEcCtD
Alfuzosin—Diarrhoea—Irinotecan—colon cancer	0.0024	0.00248	CcSEcCtD
Alfuzosin—Dry mouth—Capecitabine—colon cancer	0.0024	0.00247	CcSEcCtD
Alfuzosin—Dizziness—Vincristine—colon cancer	0.00238	0.00246	CcSEcCtD
Alfuzosin—Pruritus—Fluorouracil—colon cancer	0.00238	0.00246	CcSEcCtD
Alfuzosin—Oedema—Capecitabine—colon cancer	0.00235	0.00243	CcSEcCtD
Alfuzosin—Infection—Capecitabine—colon cancer	0.00233	0.00241	CcSEcCtD
Alfuzosin—Dizziness—Irinotecan—colon cancer	0.00232	0.0024	CcSEcCtD
Alfuzosin—Shock—Capecitabine—colon cancer	0.00231	0.00239	CcSEcCtD
Alfuzosin—Nervous system disorder—Capecitabine—colon cancer	0.0023	0.00238	CcSEcCtD
Alfuzosin—Eye disorder—Methotrexate—colon cancer	0.0023	0.00237	CcSEcCtD
Alfuzosin—Diarrhoea—Fluorouracil—colon cancer	0.0023	0.00237	CcSEcCtD
Alfuzosin—Thrombocytopenia—Capecitabine—colon cancer	0.0023	0.00237	CcSEcCtD
Alfuzosin—Tachycardia—Capecitabine—colon cancer	0.00229	0.00237	CcSEcCtD
Alfuzosin—Vomiting—Vincristine—colon cancer	0.00229	0.00237	CcSEcCtD
Alfuzosin—Cardiac disorder—Methotrexate—colon cancer	0.00228	0.00236	CcSEcCtD
Alfuzosin—Skin disorder—Capecitabine—colon cancer	0.00228	0.00236	CcSEcCtD
Alfuzosin—Rash—Vincristine—colon cancer	0.00227	0.00235	CcSEcCtD
Alfuzosin—Hyperhidrosis—Capecitabine—colon cancer	0.00227	0.00234	CcSEcCtD
Alfuzosin—Dermatitis—Vincristine—colon cancer	0.00227	0.00234	CcSEcCtD
Alfuzosin—Headache—Vincristine—colon cancer	0.00226	0.00233	CcSEcCtD
Alfuzosin—Angiopathy—Methotrexate—colon cancer	0.00223	0.00231	CcSEcCtD
Alfuzosin—Vomiting—Irinotecan—colon cancer	0.00223	0.0023	CcSEcCtD
Alfuzosin—Dizziness—Fluorouracil—colon cancer	0.00222	0.00229	CcSEcCtD
Alfuzosin—Mediastinal disorder—Methotrexate—colon cancer	0.00222	0.00229	CcSEcCtD
Alfuzosin—Rash—Irinotecan—colon cancer	0.00221	0.00228	CcSEcCtD
Alfuzosin—Dermatitis—Irinotecan—colon cancer	0.00221	0.00228	CcSEcCtD
Alfuzosin—Headache—Irinotecan—colon cancer	0.0022	0.00227	CcSEcCtD
Alfuzosin—Hypotension—Capecitabine—colon cancer	0.00219	0.00227	CcSEcCtD
Alfuzosin—Mental disorder—Methotrexate—colon cancer	0.00216	0.00223	CcSEcCtD
Alfuzosin—Nausea—Vincristine—colon cancer	0.00214	0.00221	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Capecitabine—colon cancer	0.00214	0.00221	CcSEcCtD
Alfuzosin—Vomiting—Fluorouracil—colon cancer	0.00214	0.00221	CcSEcCtD
Alfuzosin—Rash—Fluorouracil—colon cancer	0.00212	0.00219	CcSEcCtD
Alfuzosin—Dermatitis—Fluorouracil—colon cancer	0.00212	0.00219	CcSEcCtD
Alfuzosin—Headache—Fluorouracil—colon cancer	0.00211	0.00217	CcSEcCtD
Alfuzosin—Nausea—Irinotecan—colon cancer	0.00208	0.00215	CcSEcCtD
Alfuzosin—Back pain—Methotrexate—colon cancer	0.00207	0.00214	CcSEcCtD
Alfuzosin—Dyspepsia—Capecitabine—colon cancer	0.00207	0.00213	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Capecitabine—colon cancer	0.00203	0.00209	CcSEcCtD
Alfuzosin—Fatigue—Capecitabine—colon cancer	0.00202	0.00209	CcSEcCtD
Alfuzosin—Pain—Capecitabine—colon cancer	0.00201	0.00207	CcSEcCtD
Alfuzosin—Constipation—Capecitabine—colon cancer	0.00201	0.00207	CcSEcCtD
Alfuzosin—Nausea—Fluorouracil—colon cancer	0.002	0.00206	CcSEcCtD
Alfuzosin—Ill-defined disorder—Methotrexate—colon cancer	0.00199	0.00205	CcSEcCtD
Alfuzosin—Feeling abnormal—Capecitabine—colon cancer	0.00194	0.002	CcSEcCtD
Alfuzosin—Malaise—Methotrexate—colon cancer	0.00193	0.00199	CcSEcCtD
Alfuzosin—Vertigo—Methotrexate—colon cancer	0.00192	0.00199	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Capecitabine—colon cancer	0.00192	0.00198	CcSEcCtD
Alfuzosin—Urticaria—Capecitabine—colon cancer	0.00187	0.00193	CcSEcCtD
Alfuzosin—Abdominal pain—Capecitabine—colon cancer	0.00186	0.00192	CcSEcCtD
Alfuzosin—Arthralgia—Methotrexate—colon cancer	0.00182	0.00188	CcSEcCtD
Alfuzosin—Chest pain—Methotrexate—colon cancer	0.00182	0.00188	CcSEcCtD
Alfuzosin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—colon cancer	0.00181	0.00187	CcSEcCtD
Alfuzosin—Discomfort—Methotrexate—colon cancer	0.0018	0.00186	CcSEcCtD
Alfuzosin—Infection—Methotrexate—colon cancer	0.00174	0.00179	CcSEcCtD
Alfuzosin—Nervous system disorder—Methotrexate—colon cancer	0.00171	0.00177	CcSEcCtD
Alfuzosin—Thrombocytopenia—Methotrexate—colon cancer	0.00171	0.00177	CcSEcCtD
Alfuzosin—Skin disorder—Methotrexate—colon cancer	0.0017	0.00175	CcSEcCtD
Alfuzosin—Hyperhidrosis—Methotrexate—colon cancer	0.00169	0.00175	CcSEcCtD
Alfuzosin—Asthenia—Capecitabine—colon cancer	0.00168	0.00174	CcSEcCtD
Alfuzosin—Pruritus—Capecitabine—colon cancer	0.00166	0.00172	CcSEcCtD
Alfuzosin—Hypotension—Methotrexate—colon cancer	0.00163	0.00169	CcSEcCtD
Alfuzosin—Diarrhoea—Capecitabine—colon cancer	0.00161	0.00166	CcSEcCtD
Alfuzosin—Musculoskeletal discomfort—Methotrexate—colon cancer	0.00159	0.00164	CcSEcCtD
Alfuzosin—Somnolence—Methotrexate—colon cancer	0.00155	0.0016	CcSEcCtD
Alfuzosin—Dizziness—Capecitabine—colon cancer	0.00155	0.0016	CcSEcCtD
Alfuzosin—Dyspepsia—Methotrexate—colon cancer	0.00154	0.00159	CcSEcCtD
Alfuzosin—Gastrointestinal disorder—Methotrexate—colon cancer	0.00151	0.00156	CcSEcCtD
Alfuzosin—Fatigue—Methotrexate—colon cancer	0.00151	0.00156	CcSEcCtD
Alfuzosin—Pain—Methotrexate—colon cancer	0.00149	0.00154	CcSEcCtD
Alfuzosin—Vomiting—Capecitabine—colon cancer	0.00149	0.00154	CcSEcCtD
Alfuzosin—Rash—Capecitabine—colon cancer	0.00148	0.00153	CcSEcCtD
Alfuzosin—Dermatitis—Capecitabine—colon cancer	0.00148	0.00153	CcSEcCtD
Alfuzosin—Headache—Capecitabine—colon cancer	0.00147	0.00152	CcSEcCtD
Alfuzosin—Feeling abnormal—Methotrexate—colon cancer	0.00144	0.00149	CcSEcCtD
Alfuzosin—Gastrointestinal pain—Methotrexate—colon cancer	0.00143	0.00148	CcSEcCtD
Alfuzosin—Nausea—Capecitabine—colon cancer	0.00139	0.00144	CcSEcCtD
Alfuzosin—Urticaria—Methotrexate—colon cancer	0.00139	0.00143	CcSEcCtD
Alfuzosin—Abdominal pain—Methotrexate—colon cancer	0.00138	0.00143	CcSEcCtD
Alfuzosin—Asthenia—Methotrexate—colon cancer	0.00125	0.0013	CcSEcCtD
Alfuzosin—Pruritus—Methotrexate—colon cancer	0.00124	0.00128	CcSEcCtD
Alfuzosin—Diarrhoea—Methotrexate—colon cancer	0.0012	0.00124	CcSEcCtD
Alfuzosin—Dizziness—Methotrexate—colon cancer	0.00116	0.00119	CcSEcCtD
Alfuzosin—Vomiting—Methotrexate—colon cancer	0.00111	0.00115	CcSEcCtD
Alfuzosin—Rash—Methotrexate—colon cancer	0.0011	0.00114	CcSEcCtD
Alfuzosin—Dermatitis—Methotrexate—colon cancer	0.0011	0.00114	CcSEcCtD
Alfuzosin—Headache—Methotrexate—colon cancer	0.0011	0.00113	CcSEcCtD
Alfuzosin—Nausea—Methotrexate—colon cancer	0.00104	0.00107	CcSEcCtD
